Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 1,201 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $11.50, for a total transaction of $13,811.50. Following the sale, the chief financial officer directly owned 164,458 shares in the company, valued at $1,891,267. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aaron Tachibana also recently made the following trade(s):

• On Tuesday, November 25th, Aaron Tachibana sold 103,668 shares of Personalis stock. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04.

Personalis Stock Performance

Shares of PSNL opened at $10.17 on Monday. The business’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $7.47. The firm has a market capitalization of $903.10 million, a price-to-earnings ratio of -11.56 and a beta of 1.96. Personalis, Inc. has a 52 week low of $2.83 and a 52 week high of $11.50.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The company had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. As a group, research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PSNL shares. Guggenheim increased their price objective on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. BTIG Research reiterated a “buy” rating and set a $12.00 target price on shares of Personalis in a research report on Friday, January 9th. Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. HC Wainwright raised their price target on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Needham & Company LLC lifted their price objective on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Personalis presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Hedge Funds Weigh In On Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in PSNL. ARK Investment Management LLC increased its position in shares of Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares in the last quarter. AIGH Capital Management LLC lifted its holdings in Personalis by 4.5% during the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after acquiring an additional 168,143 shares in the last quarter. Aberdeen Group plc grew its stake in Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the period. Kennedy Capital Management LLC increased its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Finally, Blue Water Life Science Advisors LP increased its holdings in shares of Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after acquiring an additional 500,900 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.